In patients with acute coronary syndrome who undergo PCI, we observed that early discontinuation of ticagrelor and switching over to other P2Y12 inhibitors after discharge did not affect the composite outcome of death, recurrent myocardial infarctions, re-intervention, and major bleeding requiring transfusions. Here, P2RY12 is linked to acute coronary syndrome.